Drug Addiction - Pipeline Review, H1 2020

Drug Addiction - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2020, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 12, 31, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

LIST OF TABLES

Number of Products under Development for Drug Addiction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Drug Addiction - Pipeline by Adjuvance Technologies Inc, H1 2020
Drug Addiction - Pipeline by Aelis Farma SAS, H1 2020
Drug Addiction - Pipeline by Amygdala Neurosciences Inc, H1 2020
Drug Addiction - Pipeline by Aphios Corp, H1 2020
Drug Addiction - Pipeline by Astellas Pharma Inc, H1 2020
Drug Addiction - Pipeline by Astraea Therapeutics LLC, H1 2020
Drug Addiction - Pipeline by BioCorRx Inc, H1 2020
Drug Addiction - Pipeline by Camino Pharma LLC, H1 2020
Drug Addiction - Pipeline by Cerevel Therapeutics LLC, H1 2020
Drug Addiction - Pipeline by Charleston Laboratories Inc, H1 2020
Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2020
Drug Addiction - Pipeline by Consegna Pharma Inc, H1 2020
Drug Addiction - Pipeline by Curemark LLC, H1 2020
Drug Addiction - Pipeline by D&A Pharma SAS, H1 2020
Drug Addiction - Pipeline by Daya Drug Discoveries Inc, H1 2020
Drug Addiction - Pipeline by DD Therapeutics LLC, H1 2020
Drug Addiction - Pipeline by Denovo Biopharma LLC, H1 2020
Drug Addiction - Pipeline by Elysium Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2020
Drug Addiction - Pipeline by EncepHeal Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Drug Addiction - Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020
Drug Addiction - Pipeline by IMV Inc, H1 2020
Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2020
Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2020
Drug Addiction - Pipeline by Kdac Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by KemPharm Inc, H1 2020
Drug Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, H1 2020
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
Drug Addiction - Pipeline by MAKScientific LLC, H1 2020
Drug Addiction - Pipeline by MElkin Pharmaceuticals, H1 2020
Drug Addiction - Pipeline by Mind Medicine Inc, H1 2020
Drug Addiction - Pipeline by Mu Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by NLS Pharma Group, H1 2020
Drug Addiction - Pipeline by Novartis AG, H1 2020
Drug Addiction - Pipeline by Omeros Corp, H1 2020
Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by Ovid Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by P2D Inc, H1 2020
Drug Addiction - Pipeline by Paion AG, H1 2020
Drug Addiction - Pipeline by Protagenic Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by Saniona AB, H1 2020
Drug Addiction - Pipeline by Sen-Jam Pharmaceutical LLC, H1 2020
Drug Addiction - Pipeline by Seropeutics LLC, H1 2020
Drug Addiction - Pipeline by Sosei Heptares, H1 2020
Drug Addiction - Pipeline by SpringWorks Therapeutics Inc, H1 2020
Drug Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020
Drug Addiction - Pipeline by Vallon Pharmaceuticals Inc, H1 2020
Drug Addiction - Pipeline by Zelira Therapeutics Ltd, H1 2020
Drug Addiction - Pipeline by Zyla Life Sciences, H1 2020
Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2020
Drug Addiction - Dormant Projects, H1 2020
Drug Addiction - Dormant Projects, H1 2020 (Contd..1), H1 2020
Drug Addiction - Dormant Projects, H1 2020 (Contd..2), H1 2020
Drug Addiction - Dormant Projects, H1 2020 (Contd..3), H1 2020
Drug Addiction - Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development for Drug Addiction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Adjuvance Technologies Inc
Aelis Farma SAS
Amygdala Neurosciences Inc
Aphios Corp
Astellas Pharma Inc
Astraea Therapeutics LLC
BioCorRx Inc
Camino Pharma LLC
Cerevel Therapeutics LLC
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Consegna Pharma Inc
Curemark LLC
D&A Pharma SAS
Daya Drug Discoveries Inc
DD Therapeutics LLC
Denovo Biopharma LLC
Elysium Therapeutics Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
IMV Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Kdac Therapeutics Inc
KemPharm Inc
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
MElkin Pharmaceuticals
Mind Medicine Inc
Mu Therapeutics Inc
NLS Pharma Group
Novartis AG
Omeros Corp
Orexigen Therapeutics Inc
Ovid Therapeutics Inc
P2D Inc
Paion AG
Protagenic Therapeutics Inc
Saniona AB
Sen-Jam Pharmaceutical LLC
Seropeutics LLC
Sosei Heptares
SpringWorks Therapeutics Inc
Tonix Pharmaceuticals Holding Corp
Vallon Pharmaceuticals Inc
Zelira Therapeutics Ltd
Zyla Life Sciences
Zynerba Pharmaceuticals Inc